Intestinal Metaplasia (IM) is not cancer. IM increases your risk of a gastric cancer but it’s important to know that IM is not cancer. If you are hoping to learn more about IM because of a recent diagnosis, you’ve come to the right place.
A diagnosis of a form of pre-cancer like intestinal mucosa is the cancer sweet spot, in my opinion anyway. My experience is that this diagnosis will get your attention, hopefully change several lifestyle factors and reverse your pre-cancer status. Yes, IM is reversable.
Learn about and incorporate natural supplements to stop Helicobacter pylori (scroll down the page and email me to learn more). Get screened regularly. Eat more fruits and veggies. Eat less red meat. Eliminate animal fat from your diet. Quit smoking. Drink less alcohol. Loose that weight you’ve been meaning to loose. Now you’ve got real incentive.
If you want to take risk reduction of gastric cancer more seriously, great. Scroll down the page, post a question or a comment and I will reply to you ASAP.
“Gastric cancer remains the second most frequent cause of cancer-related mortality in the world. Screening programs in some Asian countries are impractical in the majority of other countries worldwide. Therefore, follow-up of precancerous lesions is advisable for secondary gastric cancer prevention.
Intestinal metaplasia (IM) is recognized as a precancerous lesion for gastric cancer, increasing the risk by 6-fold. IM is highly prevalent in the general population, being detected in nearly 1 of every 4 patients undergoing upper endoscopy. The IM prevalence rate is significantly higher in patients with Helicobacter pylori (H. pylori) infection, in first-degree relatives of gastric cancer patients, in smokers and it increases with patient age…
Gastric cancer risk is higher in patients with incomplete-type IM, in those with both antral and gastric body involvement, and the risk significantly increases with IM extension over 20% of the gastric mucosa.
Scheduled endoscopic control could be cost-effective in IM patients, depending on the yearly incidence of gastric cancer in IM patients, the stage of gastric cancer at diagnosis discovered at surveillance, and the cost of endoscopy.
As a pragmatic behavior, yearly endoscopic control would appear justified in all IM patients with at least one of these conditions:
(1) IM extension > 20%;
(2) the presence of incomplete type IM;
(3) first-degree relative of gastric cancer patients; and
In the remaining IM patients, a less intensive (2-3 years) could be proposed...”
“In this retrospective cohort study, researchers assessed the link between BMI and endoscopic intestinal metaplasia (IM) development. Participants included 142,832 Korean adults free of endoscopic IM and atrophic gastritis (AG) who had upper endoscopy at baseline and subsequent visits and were followed for up to 5 years.
They found that increased BMI categories were linked to increased risk of new-onset IM in a dose-response manner. Overall, they noted an independent association of obesity with increased incidence of endoscopic AG and IM in a large cohort of Korean men and women.”
“Gastric intestinal metaplasia (GIM) is a common finding from routine endoscopies. Although GIM is an early step in gastric carcinogenesis, there is controversy regarding routine surveil- lance of patients with GIM in regions with a low prevalence of gastric cancer…
We identified 25 patients with GIM who developed gastric cancers. Seventeen cases of cancer were diagnosed at the same time as the diagnosis of GIM. Eight cases of cancer were identified within a median time period of 4.6 years after a diagnosis of GIM. The overall incidence rate for the cohort was 1.72.
Among the risk factors evaluated, only family history and extent of GIM increased the risk for gastric cancer. The incidence rate for gastric cancer in patients with a positive family history was 8.12
In an analysis of patients with GIM listed in the Kaiser Permanente Southern California data- base, 2.7% were diagnosed with gastric cancer; almost 70% of cases of gastric cancer were detected at the time of GIM diagnosis. Family history and extensive metaplasia were associated with an increased risk of subsequent gastric cancer. Targeted surveillance of patients with these criteria could increase early detection of gastric cancer.